Vir Biotechnology Stock Earnings Reports

Vir Biotechnology reported progress across its oncology and hepatitis delta (HDV) programs and strengthened its financial position through collaborations and financing. Key clinical updates: VIR-5500 (PRO-XTEN dual-masked PSMA-targeted T-cell engager) showed a favorable safety profile in Phase I with no dose-limiting toxicities and no Grade 3 CRS at go-forward doses, encouraging depth and durability of responses (including in heavily pretreated patients and a CR after prior actinium-based RLT). The Phase I expansion cohorts (monotherapy late-line and combinations with ARPIs in earlier lines and mHSPC) are underway, and a registrational Phase III program is anticipated to start in 2027. Other PRO-XTEN programs (VIR-5818 HER2, VIR-5525 EGFR) continue dose escalation with preliminary readouts expected (VIR-5818 preliminary responses H2 2026). HDV program: combination of tobevibart plus elebsiran showed high rates of HDV RNA target-not-detected (TND) in Phase II SOLSTICE (88% at 96 weeks for evaluable participants on combo vs 46% on antibody alone), monthly subcutaneous dosing, favorable safety, and regulatory designations (FDA breakthrough and Fast Track; EMA PRIME). Three ECLIPSE registrational studies are on track, with ECLIPSE-1 top line data expected in Q4 2026. Corporate/financial: Vir closed a global collaboration with Astellas for VIR-5500 (deal up to $1.7B) that shifts development costs (40% Vir / 60% Astellas), includes $75M equity payment received and a $240M upfront due within 30 days of close; Vir also completed a $172.5M follow-on equity offering. Cash position was $809.3M at 3/31/26 (pre-Astellas upfront), and company expects runway into H2 2028 after accounting for recent transactions. Management emphasized disciplined capital allocation and multiple near- and mid-term catalysts across programs.